Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Ravulizumab's impact on daily life in myasthenia gravis

NCT ID NCT06909253

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This observational study follows 50 adults with generalized myasthenia gravis who are new to complement inhibitors and are receiving ravulizumab (Ultomiris) in Poland. Researchers will track changes in daily living activities and other symptoms over time. The goal is to see how well the drug works in routine medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ravulizumab (Ultomiris)
What this could lead to
If successful, this study could confirm that ravulizumab improves daily functioning in people with generalized myasthenia gravis who have not tried similar drugs before.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is also small (50 participants) and limited to Poland, which may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment within the frames of NDP in Poland.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland. * Patients willing to participate in the study and signed Informed Consent Form (ICF). * Vaccination against N. meningitidis Exclusion Criteria: * Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP. * Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis, generalized are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis, generalized

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Bydgoszcz, Poland

  • Research Site

    RECRUITING

    Gdansk, Poland

  • Research Site

    RECRUITING

    Katowice, Poland

  • Research Site

    RECRUITING

    Krakow, Poland

  • Research Site

    RECRUITING

    Lodz, Poland

  • Research Site

    RECRUITING

    Lublin, Poland

  • Research Site

    NOT_YET_RECRUITING

    Poznan, Poland

  • Research Site

    RECRUITING

    Poznan, Poland

  • Research Site

    RECRUITING

    Szczecin, Poland

  • Research Site

    WITHDRAWN

    Szczecin, Poland

  • Research Site

    RECRUITING

    Warsaw, Poland

  • Research Site

    RECRUITING

    Wroclaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.